Intec Pharma (NASDAQ:NTEC) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Tuesday.

According to Zacks, “Intec Pharma Ltd. is a biopharmaceutical company. The company focused on developing drugs through proprietary Accordion Pill platform technology. Its product candidates in clinical trial stages consists of Accordion Pill Carbidopa/Levodopa developed for the indication of treatment of Parkinson’s disease symptoms; Accordion Pill Zaleplon is being developed for the indication of treatment of insomnia, including sleep induction and the improvement of sleep maintenance. Intec Pharma Ltd. is based in JERUSALEM, Israel. “

A number of other analysts have also issued reports on NTEC. Oppenheimer boosted their price objective on Intec Pharma from $10.00 to $15.00 and gave the company an “outperform” rating in a research note on Thursday, September 21st. CIBC reiterated an “outperform” rating and set a $15.00 price objective (up from $10.00) on shares of Intec Pharma in a research note on Thursday, September 21st. ValuEngine lowered Intec Pharma from a “hold” rating to a “sell” rating in a research note on Thursday, November 16th. Finally, Maxim Group set a $8.00 price objective on Intec Pharma and gave the company a “buy” rating in a research note on Friday, November 17th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $11.20.

Shares of Intec Pharma (NASDAQ NTEC) traded up $0.05 on Tuesday, hitting $7.15. The company’s stock had a trading volume of 109,300 shares, compared to its average volume of 231,333. Intec Pharma has a 52-week low of $4.20 and a 52-week high of $9.80.

Intec Pharma (NASDAQ:NTEC) last released its quarterly earnings data on Wednesday, November 15th. The biotechnology company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.06). equities research analysts predict that Intec Pharma will post -1.35 EPS for the current year.

Large investors have recently added to or reduced their stakes in the stock. Caxton Corp bought a new stake in shares of Intec Pharma during the 3rd quarter valued at $681,000. Pura Vida Investments LLC bought a new stake in shares of Intec Pharma during the 3rd quarter valued at $895,000. Migdal Insurance & Financial Holdings Ltd. raised its stake in shares of Intec Pharma by 5.0% during the 2nd quarter. Migdal Insurance & Financial Holdings Ltd. now owns 522,200 shares of the biotechnology company’s stock valued at $2,977,000 after purchasing an additional 25,000 shares during the period. Finally, Sectoral Asset Management Inc bought a new stake in shares of Intec Pharma during the 3rd quarter valued at $3,177,000. Institutional investors own 40.16% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was copied illegally and reposted in violation of United States & international trademark and copyright laws. The legal version of this report can be accessed at https://www.watchlistnews.com/intec-pharma-ntec-downgraded-by-zacks-investment-research-to-hold/1809190.html.

Intec Pharma Company Profile

Intec Pharma Ltd is an Israel-based drug development company. It is a development stage biopharmaceutical company that develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. The Accordion Pill, a novel gastro-retentive delivery system, improves the pharmacokinetics and pharmacodynamics of various drugs.

Get a free copy of the Zacks research report on Intec Pharma (NTEC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Intec Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intec Pharma and related companies with Analyst Ratings Network's FREE daily email newsletter.